Tekrardan Hoşgeldiniz
Cointime'ın Hizmet Şartları'ini kabul etmek ve Cointime'ın Gizlilik Politikası'inin sizin için geçerli olduğunu onaylamak için "Giriş "a tıklayın.
Cointime’a Katıl
Çoktan Hesabın Var mı?
Cointime'ın <a class="underline" href="#term-of-service">Hizmet Şartları</a>'ini kabul etmek ve Cointime'ın a class="underline" href="#privacy-policy">Gizlilik Politikası</a>'inin sizin için geçerli olduğunu onaylamak için "page.Sign up "a tıklayın.
Giriş Yap
Kayıt Ol
Posta kutunuz
Gelen kutunuzu kontrol edin
Giriş yapmak için emaildeki bağlantıya tıklayın.
Kayıt olmak için emaildeki bağlantıya tıklayın.
Anergis
company
About
Anergis discovers and develops allergy vaccines based on the technology of Contiguous Overlapping Peptides for ultra-fast desensitization.
- 11 - 50
Details
- Last Funding Type
- Series A
- Last Funding Money Raised
- Fr8M
- Industries
- Biotechnology,Health Care,Life Science,Medical,Personal Health
- Founded date
- Jan 1, 2001
- Number Of Employee
- 11 - 50
- Operating Status
- Active
Anergis, a clinical-stage biopharmaceutical company, discovers and develops allergy vaccines based on the technology of Contiguous Overlapping Peptides for ultra-fast desensitization. It offers vaccines against birch pollen, ragweed pollen, and house dust mite allergies. Francois Spertini founded Anergis in 2001. Its headquarters in Lausanne in Switzerland.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
3
Fr27.50M
Anergis has raised a total of
Fr27.50M
in funding over 2 rounds. Their latest funding was raised on
Apr 4, 2016 from a Series C round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Apr 4, 2016 | Series C | Fr5M | 1 | — | — | Detail |
| Dec 3, 2014 | Series B | Fr14.50M | 1 |
Renaissance
|
— | Detail |
| Feb 7, 2014 | Series A | Fr8M | 1 |
Renaissance
|
— | Detail |
Investors
Number of Lead Investors
Number of Investors
2
1
Anergis is funded by 1 investors.
Renaissance
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
Renaissance
|
— | Series C |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
